Mergers & Acquisitions ·
Zymeworks licenses ZW209 to Roche for $55M upfront and up to $718M in milestones
ZYMEZymeworks Inc.
Zymeworks Inc. entered into a global exclusive license and collaboration agreement with F. Hoffmann-La Roche Ltd for its trispecific T-cell engager candidate ZW209, targeting DLL3-expressing tumors. Under the deal, Zymeworks receives a $55 million non-refundable upfront payment upon HSR clearance and a $40 million milestone upon Phase 1b initiation, with potential additional payments of up to $718 million based on development and commercial success. Roche will fund the ongoing Phase 1a trial and assume responsibility for subsequent global development and commercialization, while Zymeworks retains ownership of its underlying platform intellectual property. The transaction is subject to antitrust clearance. Zymeworks Inc. operates as a biotechnology company developing novel biotherapeutics and managing a portfolio of licensed healthcare assets.